Clinical trial · Observational
Rare Tumours in Children and Adolescents (STEP)
Rare Tumours in Children and Adolescents (STEP 2.0) - Register for the Documentation of Rare Tumours in Children and Adolescents
NCT05773651CI-TRIAL-00081169STEP 2 0recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the STEP registry is to collect and evaluate experience and data on the diagnosis and treatment of rare childhood tumors in order to use the knowledge gained to improve the treatment prospects for our patients. The rarity of a disease should not be a disadvantage for the young patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rare Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Rare tumor disease
- description
- Prospective epidemiological and clinical data collection of subjects with diagnosis of a rare solid tumor.
- interventionNames
- Other: Data collection
Primary outcomes (1)
- measure
- Event-free survival
- timeFrame
- 5 years
- description
- Period between study entry and failure of induction therapy, recurrence or death from any cause is measured.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Day
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of a rare solid tumor * Age at diagnosis: Neonatal period to 18 years (In the case of young adults, registration in the database and/or referral to advisory contact persons within the framework of the competence network can take place upon request and after declaration of consent.) * Information, education, written consent of the patient or the guardian * Not recorded in any of the existing clinical studies/ registers of the German Society for Pediatric Oncology and Hematology (GPOH) Exclusion Criteria: * Registration of the tumor diagnosis in a prospective therapy study/ another clinical registry of the GPOH * Lack of information, explanation and/or written consent of the patient or the legal guardian.
References
Publications (0)
Data not yet available
No reference posted for this study.